Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anakinra Plus Steroids in Giant Cell Arteritis
NCT02902731Phase 3Terminated
- Sponsor
- CHU Caen Normandie
- Start
- May 2017
- Primary completion
- Nov 2022
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in giant cell arteritis (GCA) comparing Placebo + Prednisone with Anakinra + Prednisone (2 arms). Primary endpoint: Global Relapse Rate at 26 weeks. Started May 2017; status: terminated.
02
Drugs
anakinra
03
Conditions
giant cell arteritis (GCA)
Beyond the preview
Go deeper on NCT02902731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02902731.